Cassava Sciences Inc
SAVA
查看详细走势图
2.030USD
+0.140+7.41%
收盘 02/06, 16:00（美东）报价延迟15分钟
98.07M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+7.41%
5天
+2.01%
1月
-6.88%
6月
-7.31%
今年开始到现在
+2.53%
1年
-10.57%
查看详细走势图
TradingKey Cassava Sciences Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Cassava Sciences Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业中等水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名141/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.00。中期看，股价处于下降通道。近一个月，市场表现一般，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Cassava Sciences Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Cassava Sciences Inc亮点
亮点风险
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
分析师目标
根据
1
位分析师
买入
评级
5.000
目标均价
+156.41%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Cassava Sciences Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Cassava Sciences Inc简介
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
公司代码SAVA
公司Cassava Sciences Inc
CEOBarry (Richard J)
网址https://www.cassavasciences.com/
相关品种
